Zobrazeno 1 - 10
of 106
pro vyhledávání: '"Tom Van Meerten"'
Autor:
Yusheng Lin, Ghizlane Choukrani, Lena Dubbel, Lena Rockstein, Jimena Alvarez Freile, Yuzhu Qi, Valerie Wiersma, Hao Zhang, Karl-Wilhelm Koch, Emanuele Ammatuna, Jan Jacob Schuringa, Tom van Meerten, Gerwin Huls, Edwin Bremer
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-18 (2024)
Abstract Background VISTA is a well-known immune checkpoint in T cell biology, but its role in innate immunity is less established. Here, we investigated the role of VISTA on anticancer macrophage immunity, with a focus on phagocytosis, macrophage po
Externí odkaz:
https://doaj.org/article/60adcfc1ae254d998496249d73aaad31
Autor:
Kylie Keijzer, Janneke W. de Boer, Jaap A. van Doesum, Walter Noordzij, Gerwin A. Huls, Lisanne V. van Dijk, Tom van Meerten, Anne G. H. Niezink
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract Bridging therapy before CD19-directed chimeric antigen receptor (CAR) T-cell infusion is frequently applied in patients with relapsed or refractory Large B-cell lymphoma (r/r LBCL). This study aimed to assess the influence of quantified MATV
Externí odkaz:
https://doaj.org/article/4ada8881a9dc4ff2b0f6fbb01bb5e429
Autor:
Elise R.A. Pennings, Müjde Durmaz, Otto Visser, Eduardus F.M. Posthuma, Djamila E. Issa, Martine E.D. Chamuleau, Anne M. Spanjaart, Tom van Meerten, Pim G.N.J. Mutsaers, Margot Jak, Suzanne van Dorp, Joost S.P. Vermaat, Marjolein W.M. van der Poel, Maria T. Kuipers, Frederick W. Thielen, Carin A. Uyl-de Groot, Pieternella J. Lugtenburg, Marie José Kersten, Avinash G. Dinmohamed
Publikováno v:
HemaSphere, Vol 7, p e992046d (2023)
Externí odkaz:
https://doaj.org/article/2a1ce217092646aab218c2e883f0ac51
Autor:
Diana Al-Sarayfi, Mirian Brink, Martine E. D. Chamuleau, Rolf Brouwer, Roos van Rijn, Djamila Issa, Wendy Deenik, Gerwin Huls, Rogier Mous, Joost S.P. Vermaat, Josee M. Zijlstra, Tom van Meerten, Marcel Nijland
Publikováno v:
HemaSphere, Vol 7, p e48093ff (2023)
Externí odkaz:
https://doaj.org/article/bcc7bf57df004e8e88c1b8bf6eea0e9a
Autor:
Kylie Keijzer, Anne G.H. Niezink, Janneke W. de Boer, Jaap A. van Doesum, Walter Noordzij, Tom van Meerten, Lisanne V. van Dijk
Publikováno v:
Computational and Structural Biotechnology Journal, Vol 21, Iss , Pp 1102-1114 (2023)
In the treatment of Non-Hodgkin lymphoma (NHL), multiple therapeutic options are available. Improving outcome predictions are essential to optimize treatment. The metabolic active tumor volume (MATV) has shown to be a prognostic factor in NHL. It is
Externí odkaz:
https://doaj.org/article/bdc6202699d644c7810f07582ab8af76
Autor:
Diana Al-Sarayfi, Frederik O. Meeuwes, Müjde Durmaz, Djamila E. Issa, Rolf E. Brouwer, Aart Beeker, Anna van Rhenen, Pim G. N. J. Mutsaers, Lara H. Böhmer, Marjolein W. M. van der Poel, Liane te Boome, Tom van Meerten, Martine E. D. Chamuleau, Josée M. Zijlstra, Mirian Brink, Marcel Nijland
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 9, Pp 1-4 (2022)
Externí odkaz:
https://doaj.org/article/bce0c7d4e1d241edbbcdb1d4287c2136
Autor:
Quincy Hofsink, Sabine Haggenburg, Birgit I. Lissenberg-Witte, Annoek E.C. Broers, Jaap A. van Doesum, Rob S. van Binnendijk, Gerco den Hartog, Michel S. Bhoekhan, Nienke J.E. Haverkate, Johan van Meerloo, Judith A. Burger, Joey H. Bouhuijs, Gaby P. Smits, Dorine Wouters, Ester M.M. van Leeuwen, Hetty J. Bontkes, Neeltje A. Kootstra, Sandra Vogels-Nooijen, Nynke Rots, Josine van Beek, Mirjam H.M. Heemskerk, Kazimierz Groen, Tom van Meerten, Pim G.N.J. Mutsaers, Marit J. van Gils, Abraham Goorhuis, Caroline E. Rutten, Mette D. Hazenberg, Inger S. Nijhof, Iris M.J. Kant, Thecla Graas, Belle Toussaint, Sterre de Jong, Shahan Darwesh, Sandjiv S. Mahes, Dora Kamminga, Matthijs Koelewijn, Gino Faber, Guus Beaumont, Marije D. Engel, R. Cheyenne N. Pierie, Suzanne R. Janssen, Edith van Dijkman, Jarom Heijmans, Yara Y. Witte, Rogers A. Nahui Palomino, Said Z. Omar, Sonja Zweegman, Arnon P. Kater, Caya van den Vegt, Ilonka Arends-Halbesma, Emma de Pater, Margriet J. Dijkstra, Nynke Y. Rots, Esther Siteur-van Rijnstra, Dennis M. de Rooij, Rogier W. Sanders, Meliawati Poniman, Wouter Olijhoek, Jacqueline van Rijswijk, Tim Beaumont, Lusia Çetinel, Louis Schellekens, Yvonne M. den Hartogh, Jacqueline Cloos, Suzanne S. Weijers, Saïda Tonouh-Aajoud, Selime Avci, Elianne Roelandse-Koop, Willem A. Dik
Publikováno v:
EClinicalMedicine, Vol 61, Iss , Pp 102040- (2023)
Summary: Background: Patients with haematological malignancies have impaired antibody responses to SARS-CoV-2 vaccination. We aimed to investigate whether a fourth mRNA COVID-19 vaccination improved antibody quantity and quality. Methods: In this coh
Externí odkaz:
https://doaj.org/article/b6705aeb989e44eeb7ee10f048616947
Autor:
Myra Langendonk, Mathilde R. W. de Jong, Nienke Smit, Jonas Seiler, Bart Reitsma, Emanuele Ammatuna, Andor W. J. M. Glaudemans, Anke van den Berg, Gerwin A. Huls, Lydia Visser, Tom van Meerten
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 3, Pp 1-9 (2022)
Abstract Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype. Despite the proven efficacy of combined immunochemotherapy (R-CHOP) in the majority of patients, ~40% of DLBCL patients do not respond or will relapse and consequentl
Externí odkaz:
https://doaj.org/article/9ba671588e2d474e85d30f74272bdcdf
Autor:
Ewa Cendrowicz, Lisa Jacob, Shirley Greenwald, Ami Tamir, Iris Pecker, Rinat Tabakman, Lucy Ghantous, Liat Tamir, Roy Kahn, Jasmine Avichzer, Alexandra Aronin, Shira Amsili, Elina Zorde-Khvalevsky, Yosi Gozlan, Martijn Vlaming, Gerwin Huls, Tom van Meerten, Michal Elhalel Dranitzki, Adam Foley-Comer, Yaron Pereg, Amnon Peled, Ayelet Chajut, Edwin Bremer
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-16 (2022)
Abstract Background Treatment of Diffuse Large B Cell Lymphoma (DLBCL) patients with rituximab and the CHOP treatment regimen is associated with frequent intrinsic and acquired resistance. However, treatment with a CD47 monoclonal antibody in combina
Externí odkaz:
https://doaj.org/article/88f427a2882642b7b2f32986f378f0e2
Autor:
Martijn Vlaming, Vrouyr Bilemjian, Jimena Álvarez Freile, Harm Jan Lourens, Nienke van Rooij, Gerwin Huls, Tom van Meerten, Marco de Bruyn, Edwin Bremer
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
Abstract The presence of T cells that are dimly positive for the B cell marker CD20 is well-established in autoimmunity and correlates with disease severity in various diseases. Further, we previously identified that the level of CD20-positive T cell
Externí odkaz:
https://doaj.org/article/5b0c52b51ccf44eb9aa17073f9d75dfd